Adocia SA (EPA: ADOC)
France flag France · Delayed Price · Currency is EUR
5.92
+0.12 (2.07%)
Dec 23, 2024, 5:35 PM CET

Adocia Company Description

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases.

Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins.

The company’s clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; and BioChaperone LisPram, a combination of prandial insulin with pramlintide, as well as M1Pram, a combination of insulin M1 and pramlintide.

Its preclinical pipeline includes products for the treatment of diabetes and obesity comprising AdoShell Islets, an implant containing islets of Langerhans; AdOral Sema, an oral delivery of semaglutide; and AdoGel Sema for the long-term delivery of therapeutic agents.

The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories.

Adocia SA was incorporated in 2005 and is headquartered in Lyon, France.

Adocia SA
Country France
Founded 2005
Industry Biotechnology
Sector Healthcare
Employees 78
CEO Olivier Soula

Contact Details

Address:
115 Avenue Lacassagne
Lyon, 69003
France
Phone 33 4 72 61 06 10
Website adocia.com

Stock Details

Ticker Symbol ADOC
Exchange Euronext Paris
Fiscal Year January - December
Reporting Currency EUR
ISIN Number FR0011184241
SIC Code 2836

Key Executives

Name Position
Olivier Soula M.B.A., Ph.D. Co-Founder, Chief Executive Officer and Director
Dr. Gérard Soula M.B.A., Ph.D. Co-Founder and Chairman of the Board
Mathieu-William Gilbert Chief Operating Officer and Chief Financial Officer
Jeremy Benattar Eng., Pharm.D. Marketing and Strategy Director
Geraldine Favre Soula Director of Human Resources
Dr. Bertrand Alluis Head of the Analysis Department and Project Manager
Dr. David Duracher Head of the Pharmaceutical Development and Physical Chemistry Departments and Project Manager
Dr. Richard Charvet Head of Chemistry Department and Project Manager
Dr. Grégory Meiffren Head of the Biology Department and Project Manager
Rosy Eloy M.D. Chief Medical Officer